Humana (NYSE:HUM) – Jefferies Group raised their FY2019 earnings per share estimates for shares of Humana in a note issued to investors on Thursday, April 12th. Jefferies Group analyst D. Windley now forecasts that the insurance provider will earn $17.22 per share for the year, up from their previous estimate of $16.65. Jefferies Group has a “Buy” rating and a $221.00 price target on the stock.
Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 19th. Oppenheimer lifted their price objective on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Leerink Swann lifted their price objective on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. ValuEngine downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, December 19th. Finally, JPMorgan Chase lifted their price objective on Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Seven equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $272.21.
Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. Humana’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.34 EPS.
Several institutional investors have recently added to or reduced their stakes in HUM. Caxton Associates LP bought a new stake in shares of Humana during the 3rd quarter valued at about $463,000. Cubist Systematic Strategies LLC grew its stake in shares of Humana by 1,327.1% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,738 shares of the insurance provider’s stock valued at $1,154,000 after purchasing an additional 4,406 shares during the period. Piedmont Investment Advisors LLC grew its stake in shares of Humana by 0.9% during the 3rd quarter. Piedmont Investment Advisors LLC now owns 31,097 shares of the insurance provider’s stock valued at $7,576,000 after purchasing an additional 286 shares during the period. Sterling Capital Management LLC grew its stake in shares of Humana by 1,316.4% during the 3rd quarter. Sterling Capital Management LLC now owns 14,858 shares of the insurance provider’s stock valued at $3,620,000 after acquiring an additional 13,809 shares during the period. Finally, Fieldpoint Private Securities LLC bought a new position in shares of Humana during the 3rd quarter valued at approximately $115,000. Institutional investors and hedge funds own 96.43% of the company’s stock.
In other Humana news, insider M Todoroff Christopher sold 16,389 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the completion of the sale, the insider now directly owns 13,447 shares in the company, valued at approximately $3,676,006.39. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Cynthia H. Zipperle sold 1,196 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $273.33, for a total value of $326,902.68. Following the sale, the senior vice president now owns 7,771 shares of the company’s stock, valued at $2,124,047.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,660 shares of company stock valued at $8,668,218. Corporate insiders own 0.60% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.70%. The ex-dividend date is Wednesday, March 28th. Humana’s payout ratio is currently 17.08%.
Humana declared that its Board of Directors has initiated a share buyback plan on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: “FY2019 EPS Estimates for Humana (HUM) Raised by Analyst” was first published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/13/fy2019-eps-estimates-for-humana-hum-raised-by-analyst.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.